FDA Labeling Change Rule Is Most Prominent Item On Agency’s To-Do List
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS’s semi-annual inventory of rulemaking actions under development includes six prescription drug-related rules.
You may also be interested in...
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
FDA Safety Labeling Change Guidance Seeks To Ease Class Confusion
Final guidance implementing FDAAA authority explains how disagreements between the agency and one or more sponsors could affect the timeline for safety-related labeling changes across a class of products.